483 related articles for article (PubMed ID: 28104258)
21. Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β.
Zecca C; Riccitelli GC; Calabrese P; Pravatà E; Candrian U; Guttmann CR; Gobbi C
BMC Neurol; 2014 Feb; 14():38. PubMed ID: 24576156
[TBL] [Abstract][Full Text] [Related]
22. Adherence to Polyethylene Glycol Treatment in Children with Functional Constipation Is Associated with Parental Illness Perceptions, Satisfaction with Treatment, and Perceived Treatment Convenience.
Koppen IJN; van Wassenaer EA; Barendsen RW; Brand PL; Benninga MA
J Pediatr; 2018 Aug; 199():132-139.e1. PubMed ID: 29754864
[TBL] [Abstract][Full Text] [Related]
23. Interferon-beta(1b) treatment in neuromyelitis optica.
Tanaka M; Tanaka K; Komori M
Eur Neurol; 2009; 62(3):167-70. PubMed ID: 19590215
[TBL] [Abstract][Full Text] [Related]
24. Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.
Zettl UK; Bauer-Steinhusen U; Glaser T; Czekalla J; Hechenbichler K; Limmroth V; Hecker M
Adv Ther; 2016 May; 33(5):834-47. PubMed ID: 27090116
[TBL] [Abstract][Full Text] [Related]
25. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.
Eagle T; Stuart F; Chua AS; LaRussa A; Leclaire K; Cook SL; Chitnis T; Weiner HL; Glanz BI; Healy BC
Mult Scler Relat Disord; 2017 Nov; 18():196-201. PubMed ID: 29141809
[TBL] [Abstract][Full Text] [Related]
26. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
Reynolds MW; Stephen R; Seaman C; Rajagopalan K
J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
[TBL] [Abstract][Full Text] [Related]
27. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis.
Mohr DC; Goodkin DE; Likosky W; Gatto N; Baumann KA; Rudick RA
Arch Neurol; 1997 May; 54(5):531-3. PubMed ID: 9152109
[TBL] [Abstract][Full Text] [Related]
28. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
[TBL] [Abstract][Full Text] [Related]
29. Cultural adaptation and validation of a peninsular Spanish version of the MSTCQ
Muntéis Olivas E; Navarro Mascarell G; Meca Lallana J; Maestre Martínez A; Pérez Sempere Á; Gracia Gil J; Pato Pato A
Neurologia; 2017; 32(1):29-39. PubMed ID: 25697827
[TBL] [Abstract][Full Text] [Related]
30. Risk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome.
Jernas Ł; Wencel J; Wiak A; Bieniek M; Bartosik-Psujek H
PLoS One; 2016; 11(10):e0157950. PubMed ID: 27695075
[TBL] [Abstract][Full Text] [Related]
31. Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b.
Minagar A; Ma W; Zhang X; Wang X; Zhang K; Alexander JS; Gonzalez-Toledo E; Albitar M
Neurol Res; 2012 Jul; 34(6):611-8. PubMed ID: 22709658
[TBL] [Abstract][Full Text] [Related]
32. Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.
Zecca C; Disanto G; Mühl S; Gobbi C
BMC Neurol; 2017 Sep; 17(1):171. PubMed ID: 28870152
[TBL] [Abstract][Full Text] [Related]
33. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
Kleinman NL; Beren IA; Rajagopalan K; Brook RA
J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
[TBL] [Abstract][Full Text] [Related]
34. Sleep quality, daytime sleepiness, fatigue, and quality of life in patients with multiple sclerosis treated with interferon beta-1b: results from a prospective observational cohort study.
Kotterba S; Neusser T; Norenberg C; Bussfeld P; Glaser T; Dörner M; Schürks M
BMC Neurol; 2018 Aug; 18(1):123. PubMed ID: 30143019
[TBL] [Abstract][Full Text] [Related]
35. Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis.
Ossege LM; Sindern E; Patzold T; Malin JP
Int Immunopharmacol; 2001 Jun; 1(6):1085-100. PubMed ID: 11407304
[TBL] [Abstract][Full Text] [Related]
36. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study.
Patti F; Penaherrera JN; Zieger L; Wicklein EM
BMC Neurol; 2021 Aug; 21(1):324. PubMed ID: 34425763
[TBL] [Abstract][Full Text] [Related]
38. Self-reported medication adherence and treatment satisfaction in patients with epilepsy.
Sweileh WM; Ihbesheh MS; Jarar IS; Taha AS; Sawalha AF; Zyoud SH; Jamous RM; Morisky DE
Epilepsy Behav; 2011 Jul; 21(3):301-5. PubMed ID: 21576040
[TBL] [Abstract][Full Text] [Related]
39. Lymphocytes in the treatment with interferon beta-1 b.
Pavelek Z; Vyšata O; Klímová B; Andrýs C; Vokurková D; Vališ M
Mult Scler Relat Disord; 2017 Nov; 18():29-32. PubMed ID: 29141817
[TBL] [Abstract][Full Text] [Related]
40. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
